Our Story
InnoCare was started from a group highly motivated scientists with a single focus, to provide patients around the world with modern, innovative drugs in the battle against cancers and autoimmune diseases.
Founded in 2015, we have had many distinguished accomplishments, including the submission of our first NDA for Orelabrutinib, a highly selective BTK inhibitor.
2015
- Our Company was incorporated
2016
- Beijing and Nanjing Research and Development centers established and commenced operations
2017
- Phase 1 clinical trial of orelabrutinib (ICP-022) initiated
2018
- First patient of MCL and CLL/SLL dosed
- ICP-105 Phase 1 clinical trials initiated
- ICP-192 Phase 1 clinical trials initiated
- Closed Series C&D rounds of financing raising in aggregate US$235.5 million
- InnoCare Guangzhou, a manufacturing subsidiary, was established and commenced operations
2019
- Patient enrollment for MCL and CLL/SLL Phase 2 trial was completed
- CLL NDA submitted to the CDE
- Opened the U.S. office
- Orelabrutinib (ICP-022) IND was approved in US by FDA
2020
2021
2022
- 2015
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
